Research, Development and Licensing
- Challenge: Clinical use requires huge amounts of Bone morphogenetic protein-2 (BMP-2) due to unfavourable release kinetics. This leads to high costs limiting clinical use.
- Solution: Morphoplant's coating technology for BMP-2 immobilization allows for controlled release therefore minimizing the amount of BMP-2 needed for osteoinduction. Morphoplant’s coating technology is applicable to bovine, human, synthetic and phycogenic bone replacement materials.
- highly osteoinductive bone replacement materials
- no need for autologous bone
- accelerated bony integration
- expanded indication spectrum
- variation of controlled release according to clinical applications
